Application 211413
- Type
- NDA
- Sponsor
- HQ SPCLT PHARMA
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | CEFAZOLIN SODIUM | CEFAZOLIN SODIUM | POWDER;INTRAVENOUS | EQ 2GM BASE/VIAL | Yes | Yes |
| 002 | CEFAZOLIN SODIUM | CEFAZOLIN SODIUM | POWDER;INTRAVENOUS | EQ 3GM BASE/VIAL | Yes | Yes |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N211413-001 | CEFAZOLIN SODIUM | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | |
| N211413-002 | CEFAZOLIN SODIUM | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-03-08 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N211413-002 | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-03-08 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 8072bd15b7f6… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | 3f0d92c62455… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N211413-001 | CEFAZOLIN SODIUM | EQ 2GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2023-05-08 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N211413-002 | CEFAZOLIN SODIUM | EQ 3GM BASE/VIAL | POWDER / INTRAVENOUS | RLD, RS | 2024-03-08 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cefazolin | CEFAZOLIN | WG Critical Care, LLC | 4f3a9248-a354-4c77-bf5b-9eed38f00219 | 2026-02-27 | Warnings, Adverse reactions | 211413 NDA211413 |